Stallergenes and CMC sign manufacturing agreement for recombinant Bet v 1
14-May-2007
By:Diana Morgan
Antony, France; Copenhagen, Denmark (May 14, 2007) – STALLERGENES SA and CMC Biopharmaceuticals A/S announce today that they have entered into an agreement for development and supply of recombinant Bet v 1 (rBet v 1) purified bulk.
Bet v 1 is the protein that embodies most of the allergenicity of birch pollen, so called the major allergen of birch pollen.
CMC Biopharmaceuticals will scale up the manufacturing of GMP purified recombinant Bet v 1 and produce batches for Phase III clinical trials and commercial supply.
Read the entire pdf press release.
